Why AcelRx Pharmaceuticals Inc Stock Boomed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of AcelRx Pharmaceuticals (NASDAQ: ACRX  ) , a health care company developing the Zalviso pain-managing drug delivery system, jumped by as much as 11% today after the company confirmed its July 27 PDUFA date for Zalviso with the FDA.

So what: According to the company's press release, rumors had swirled that regulators already had approved the device -- but so far, AcelRx noted that it hasn't heard an answer over its regulatory filing for Zalviso. Investors, however, have rallied around the stock as analysts grow optimistic over an FDA approval for Zalviso. Piper Jaffrey noted last month that it expects a "timely approval" of the device around its PDUFA date, particularly after Zalviso posted strong safety and efficacy data in earlier clinical trials.

Now what: Signs are looking good for Zalviso's approval moving forward, and today's stock jump points to investor confidence in just that outcome. There's a sizable opportunity here for AcelRx: The company's drug delivery and pain-management system is aiming to compete with traditional IV-delivered pain control in hospitals, a practice AcelRx notes can lead to infections, human errors, and other potential hazards.

Zalviso has already won its share of supporters. AcelRx inked a deal worth up to $250 million to sell the system's European and Australian rights to German company Grunenthal GmbH, and Piper Jaffray foresees up to $300 million to $400 million in peak U.S. sales for the system if approved.

Risk-free for 30 days: The Motley Fool's flagship service
Tom and David Gardner founded The Motley Fool over 20 years ago with the goal of helping the world invest... better. Their flagship service, Stock Advisor, has helped thousands of investors take control of their financial lives and beat the market. Click here to sign up today.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3044890, ~/Articles/ArticleHandler.aspx, 12/20/2014 12:24:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement